Skip to content
Screener

Ashland ASH Life Sciences — Research And Development Expense

Other segment segments

Personal Care And Household
$6M0.0%
Specialty Additives
$4M+33.3%
Unallocated And Other
$1M
Intermediates And Solvents
$0

Similar metrics at other companies

Beam Therapeutics logo
BEAMExternal Research And Development Expenses — Research And Development Expense
$30.08M-12.6%
Solid Biosciences Inc. logo
SLDBInternal Research And Development Expense — Research And Development Expense
$9.06M+33.9%
Disc Medicine logo
IRONInternal Research And Development — Research And Development Expense
$11.31M+67.6%
Helios Technologies logo
HLIOUnallocated Expenses — Research And Development Expense
$0
Dianthus Therapeutics logo
DNTHDiscovery Expenses — Research And Development Expense
$1.36M+51.4%
Innoviva, Inc. logo
INVAInternal Expenses — Research And Development Expense
$2.73M+127%

Other financials

Income statement

See full
Revenue$497.0M+7.3%
Gross profit$170.0M+28.8%
Operating income$43.0M+106%
Net income$16.0M+102%
EPS (diluted)$0.35+102%

Balance sheet

See full
Cash & equivalents$440.0M+113%
Total debt$1.5B-0.6%
Total equity$1.9B-1.0%
Total assets$4.6B-0.9%

Cash flow

See full
Operating cash flow$120.0M+4.3%
CapEx$20.0M0.0%
Free cash flow$100.0M+5.3%

Valuation

See full
Market cap$3.45B+46.4%
Enterprise value$4.49B+23.5%
P/E172.6×
P/S1.9×+0.6×

Profitability

See full
Gross margin31.5%+1.4pp
Operating margin4.1%
Net margin1.1%+0.5pp
FCF margin13.6%+9.7pp

Returns & leverage

See full
Return on equity1.1%+0.5pp
Debt / equity0.8×0.0×
Current ratio+0.4×

Where this comes from

Reported directly by Ashland in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.

The source filing: Ashland’s 10-Q, filed July 29, 2026.

Filed
Jul 29, 2026, 5:17 PM EDT
Fiscal quarter
Q3 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-324226
(In millions - unaudited)Three months ended / June 30 / 2026Three months ended / June 30 / 2025Nine months ended / June 30 / 2026Nine months ended / June 30 / 2025
Unallocated and other38498495
$99$106$264$268
Research and development expense
Life Sciences$4$4$11$12
Personal Care661719
Specialty Additives43108
Intermediates1
Total operating segments14133939

ITEM 1. FINANCIAL STATEMENTS

FAQ

What is Ashland's life sciences — research and development expense?
Ashland (ASH) reported life sciences — research and development expense of $4M in Q2 2026.
How has Ashland's life sciences — research and development expense changed year-over-year?
Ashland's life sciences — research and development expense decreased by 0.0% year-over-year, from $4M to $4M.
What is the long-term trend for Ashland's life sciences — research and development expense?
Over 2 years (2023 to 2025), Ashland's life sciences — research and development expense has grown at a 3.5% compound annual growth rate (CAGR), from $14M to $15M.
What does life sciences — research and development expense mean?
This represents the investment made by the segment in discovering, developing, and improving products, technologies, or processes. It is a leading indicator of the segment's commitment to innovation and long-term competitive advantage. Sustained investment here is typically necessary to maintain market position and drive future revenue growth.

Ask your AI about Ashland's life sciences — research and development expense.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude